Asteroid Day Gains Momentum with U.S. Recognition from Flagstaff, Coconino County, U.S. Senate, and Vera C. Rubin Observatory Data Release
Since its inception, hundreds of independently organized Asteroid Day events have been taking place globally, calling attention to the critical need for awareness of both the dangers and possibilities associated with asteroids. This year, the movement celebrates official recognition from Flagstaff, Arizona, Coconino County, Arizona, and the United States Senate, marking a pivotal moment in bringing asteroid awareness to the forefront of public consciousness in the USA. Notably, these local, city, and national recognitions are the first in the world to highlight the profound importance of Asteroid Day in inspiring the next generation through Science, Technology, Engineering, Arts, and Mathematics (STEAM) activities.
"As a retired astronaut, I know firsthand the importance of space research. Asteroid Day is a critical initiative that not only raises awareness about planetary defense but also ignites curiosity and inspires the next generation of scientists, engineers, and explorers to pursue careers in STEAM. I'm proud to introduce a resolution recognizing Asteroid Day in the United States Senate," said retired astronaut and U.S. Senator Mark Kelly (D-AZ). The Senate resolution was introduced in partnership with U.S. Senator John Cornyn (R-TX).
"B612 Foundation, as the founding sponsor of Asteroid Day and a leading voice in asteroid analysis and mapping and planetary defense, championed the development of the 100x Declaration, a call to action that launched the global Asteroid Day movement. 'We are humbled and excited to see that in addition to the United Nations recognizing Asteroid Day on 6 December 2016, both Arizona and the United States government are now following suit,' said Danica Remy, Asteroid Day Co-founder and President of B612. 'I am additionally delighted that the US National Science Foundation and Department of Energy Vera Rubin Observatory is using Asteroid Day to release its first data product for scientists and the public. This growing momentum highlights the critical importance of understanding asteroid risks and opportunities for humanity's future."
"This global movement would not have been possible without the visionary leadership of the Government of Luxembourg, particularly the contributions of former Deputy Prime Minister Etienne Schneider, today's CEO of Luxembourg's state innovation agency Luxinnovation Mario Grotz, and today's CEO of Luxembourg Space Agency (LSA) Marc Serres. Their efforts, alongside former NASA Ames Director Pete Worden and former Consul General and Executive Director Luxembourg Trade & Investment San Francisco Georges Schmit, as well as the dedicated leadership of the Asteroid Foundation board of directors, have amplified the Asteroid Day program globally," said Markus Payer, Chair of Asteroid Foundation. "The Luxembourg government's invitation to Asteroid Day co-founders, Apollo 9 astronaut Rusty Schweickart, Danica Remy, Grig Richters and Dr. Brian May, to establish the Asteroid Foundation in Luxembourg in 2017 provided the essential groundwork. This commitment was further solidified by the ongoing leadership of the LSA, which has played an instrumental role in supporting Asteroid Day's global program, alongside Luxembourg's rich local and cross-European in-person year-round initiatives."
Asteroid Day serves as a global platform to educate the public about the exciting prospects of asteroid resource utilization and their role in understanding the origins of our universe, while also covering the role of asteroids in our solar system and the science and technology being developed to detect, track, and ultimately mitigate potential threats.
About Asteroid Foundation: A Luxembourg based nonprofit, founded 2017, is the home of Asteroid Day and is dedicated to promoting public awareness and education about asteroids and space. Through global events, educational initiatives, and strategic partnerships, the Foundation strives to inspire a greater understanding of asteroids and their significance to our planet and humanity's future in space. For more information, visit AsteroidFoundation.org or follow on social: Facebook, LinkedIn or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
New Study Demonstrates Superiority of EggNest™ Complete Radiation Protection System in Comprehensive Protection for the Entire Interventional Team
MINNEAPOLIS, Aug. 13, 2025 /CNW/ -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team. The study, titled "Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems," compared the EggNest™ Complete system with the Rampart IC system and a no-shielding condition using an anthropomorphic phantom. The results showed that both the EggNest™ Complete and Rampart IC systems significantly reduced radiation exposure for the operator and assistant positions compared to no shielding. However, the EggNest™ Complete system provided additional significant protection for staff at the head of the bed and the nursing positions, a benefit not observed with the Rampart IC system. "From the beginning, Egg Medical has had three guiding principles: we need to protect the entire team from scatter radiation, we can't interfere with workflow or patient access, and the reduction in radiation exposure must be nearly complete. The study by Riley et al shows very clearly that the EggNest Complete system dramatically reduces radiation exposure for everyone in the room, and that the operator and assistant are almost completely protected. That is a marked improvement to safety for everyone who works in x-ray guided procedures," said Dr. Robert Wilson, CEO of Egg Medical. The study's authors note that interventional cardiology procedures expose healthcare professionals to prolonged ionizing radiation, which poses significant health risks including heightened rates of malignancy, cataracts, and orthopedic injuries. Traditional lead aprons, while offering some protection, are heavy (up to 25 pounds) and can lead to musculoskeletal injuries. A recent SCAI survey found that 66% of operators reported musculoskeletal pain attributed to their time in the cardiac catheterization laboratory. "It's a community effort to bring the issue of healthcare worker safety to the forefront of our industry. We deserve the same level of protection we strive to give to patients. This study highlights that Egg Medical's EggNest Complete System sets a new standard for what ALARA (As Low As Reasonably Achievable) means today," said Robert Riley, MD, a co-author of the study. The study's findings indicate that a comprehensive shielding system like EggNest™ Complete is crucial for ensuring the safety of all interventional lab personnel, including operators, assistants, nurses, and other staff. This is particularly important for complex procedures where staff may be positioned in areas with limited traditional shielding and higher cumulative exposure. The authors of a separate commentary on the study commended the findings, emphasizing that these results align with the Society for Cardiovascular Angiography & Interventions' mission to advance occupational safety and are essential for sustaining the interventional cardiology workforce. Comparative Effectiveness of 2 Next-Generation Scatter Radiation Shielding Systems. Stephen Kidd, MD, Robert F. Riley, MD, MS, Juliette Power, MD, Brian Stegman, MD, Thom G. Dahle, MD. Division of Cardiology, Overlake Medical Center, Bellevue, Washington. Division of Cardiology, St. Cloud Hospital, St. Cloud, Minnesota. Journal of the Society for Cardiovascular Angiography & Interventions (2025), doi: About Egg Medical Egg Medical is a global leader in radiation protection technologies. Headquartered in Minnesota, the company was founded with the goal to reduce the scatter radiation exposure of physicians, surgeons, nurses, technicians and others who use x-ray imaging to perform life-saving diagnostic and therapeutic procedures for patients. More information about Egg Medical is available at
Cision Canada
3 hours ago
- Cision Canada
Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy Français
Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy. The approval is based on data from the Phase 3 KEYNOTE-689 trial, which demonstrated positive clinical outcomes in patients with resectable locally advanced HNSCC whose tumours expressed PD-L1 (CPS ≥ 1). Perioperative KEYTRUDA ® in combination with adjuvant radiotherapy with or without cisplatin reduced the risk of event free survival (EFS) by 30% (Hazard Ration [HR]=0.70 [95% Confidence Interval [CI]: 0.55–0.89; p=0.0014]) compared to adjuvant radiotherapy with or without cisplatin. "We know that head and neck squamous cell carcinomas present significant treatment challenges because of their complexity," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "The introduction of a perioperative anti-PD-1 treatment option for eligible patients in Canada represents an important development with the potential to make a meaningful difference for patients and their families impacted by this disease." About KEYNOTE-689 KEYNOTE-689 is a randomized, multicenter, open label, active-controlled Phase III trial ( NCT03765918) evaluating pembrolizumab in patients with resectable locally advanced (Stage III-IVA) head and neck squamous cell carcinoma (HNSCC). Randomization was stratified by primary tumour site (oropharynx/oral cavity vs. larynx vs. hypopharynx), tumour stage (III vs. IVA) and PD-L1 status (Tumour Proportion Score [TPS] ≥ 50% vs TPS < 50%). The study enrolled 714 patients who were randomized (1:1) to receive one of two treatment arms: Neoadjuvant pembrolizumab 200 mg for 2 cycles every 3 weeks prior to surgical resection. Within 6 weeks following surgery, pembrolizumab 200 mg for 3 cycles in combination with either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. This was followed by pembrolizumab 200 mg every 3 weeks for up to 12 cycles. No neoadjuvant treatment prior to surgery. Within 6 weeks following surgery, either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. High-risk pathological features included the presence of positive margins or extranodal extension following surgical resection. Treatment with pembrolizumab continued until completion of the treatment (17 cycles), disease progression that precluded definitive surgery, disease recurrence in the adjuvant phase, disease progression for those who did not undergo surgery or had incomplete resection and entered the adjuvant phase, or unacceptable toxicity. Assessment of tumour status was performed prior to surgery at Week 6 in the neoadjuvant phase. Following the start of the adjuvant phase, assessment of tumour status was performed 12 weeks after the end of RT ± cisplatin treatment and then every 3 months until the end of Year 3; then every 6 months thereafter up to the end of Year 5. The primary efficacy outcome measure was event-free survival (EFS) by Blinded Independent Central Review (BICR) defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant disease progression or recurrence, or death due to any cause. Secondary primary malignancy was not considered an event. An additional efficacy outcome measure was overall survival (OS). Among the CPS ≥1 population, at the time of the first pre-specified interim analysis, the EFS HR was 0.70 (95% CI, 0.55-0.89; p=0.00140) and the number of events was 128 (37%) in the pembrolizumab arm versus 156 (47%) in the RT +/- cisplatin arm. The median EFS was 59.7 months (95% CI, 37.9-not reached) versus 29.6 months (95% CI, 19.5-41.9), in the pembrolizumab and RT +/- cisplatin arms respectively. The most common treatment-related adverse events for patients treated with pembrolizumab in KEYNOTE-689 (reported in at least 20% of patients) were radiation skin injury and stomatitis. The most common Grade 3-5 treatment-related adverse events (reported in at least 5% of patients) were stomatitis (11.6%), lymphocyte count decreased (5.5%), and neutrophil count decreased (5.3%). For complete information, refer to the KEYTRUDA ® product monograph. About head and neck cancer Head and neck cancer are comprised of a group of cancers that develop in or around the mouth, nose, throat, sinuses, larynx or voice box and saliva glands. In Canada, it was estimated that there were approximately 8,100 new cases of head and neck cancer diagnosed and more than 2,100 deaths from the disease in 2024. Most head and neck cancers begin in the squamous cells that line the mucosal surfaces such as the mouth, throat and voice box. There are several factors that greatly increase the risk of developing head and neck cancer, including tobacco and alcohol use, human papillomavirus (HPV), occupation exposure to certain substances, genetic history and pool oral hygiene. About KEYTRUDA ® KEYTRUDA ® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA ® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells. KEYTRUDA ® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn @MerckCanada. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ® Merck Sharp & Dohme LLC. Used under license. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NON-04264 Media Contacts:
Cision Canada
3 hours ago
- Cision Canada
Praxis Spinal Cord Institute, Technology for Living and MIMIC Systems Vancouver pilot Novel Solid-State Cooling and Heating System Advancing Climate Resiliency for People with Disabilities
Pilot marks Canadian first in climate-resilient, refrigerant-free heating & cooling technology to assess climate equity. VANCOUVER, BC, Aug. 13, 2025 /CNW/ - Through the SCI Climate Futures initiative, Praxis Spinal Cord Institute and Technology for Living (TFL) are advancing innovative solutions to support the health resiliency of individuals vulnerable to rising temperatures. Today, Praxis and TFL are proud to announce the successful installation of the first pilot MIMIC solid-state climate control system in the Vancouver home of an individual living with spinal cord injury (SCI). This milestone was made possible with the generous support of the Gore Mutual Insurance Collaborative Climate and Equity Partnerships grant. For individuals living with SCI, multiple sclerosis (MS), and other chronic conditions that impair the body's natural ability to regulate temperature, prolonged exposure to heat, especially temperatures exceeding 29°C can be life-threatening. Without access to effective cooling technologies, these individuals face daily health risks, including muscle spasms, disorientation, and hospitalization. "At Gore Mutual, we believe that climate resilience must be inclusive. Supporting innovative solutions like the MIMIC system aligns with our commitment to equity and sustainability," said Gaby Polanco Sorto, VP, Purpose, Sustainability and Office of the CEO at Gore Mutual Insurance. "As the founding partner of The Climate and Equity Lab, we remain committed to deepening our collective understanding of how climate change impacts vulnerable communities, and we're proud to partner with organizations that are creating real-world impact for Canadians living with disabilities." MIMiC Systems unveils a solid-state solution for indoor climate control for the built environment, designed to eliminate refrigerants or moving parts. Offering both heating and cooling in a single, compact unit, the system provides a quiet alternative to traditional HVAC, ideal for property owners seeking simplicity, sustainability, and performance. The installation faced several delays due to the complexity of approving novel clean tech in BC, with support from the City of Vancouver essential to the launch of the pilot, highlighting the need for regulatory change to effectively meet the climate resiliency needs of Canadians living with disabilities. "It's been a great experience. The unit is beautiful, and we're really happy our family was chosen for the pilot. Just walking into a cool home makes such a difference. I hope this system helps us stay comfortable while using less energy during the summer"— Pilot PLEX (person with spinal cord injury, lived experience) homeowner. " We're building a new standard for thermal comfort - one that's easy to install, built to last, and aligned with our planet's needs.", said Berardo Matalucci, CEO of MIMiC. "SCI Climate Futures initiative helped us to deploy our first unit to provide heating and cooling to those who need it the most. We're humbled and grateful for all the support. We'd also like to give a huge shoutout to Terra Mechanical Ltd. They've been a fantastic partner for our first install". The installation was completed by Terra Mechanical Ltd., BC HVAC and controls specialists, with support from the MIMIC, Praxis, and TFL teams. It involved close collaboration with the homeowner and building management to ensure compatibility, accessibility, and safety. Valuable feedback gathered during the process is already informing future product refinements. Why It Matters The SCI Climate Futures initiative was launched in response to British Columbia's escalating heat crises, which disproportionately affect people with disabilities. Phase 2 expands the scope to test and validate built-environment technologies that offer year-round thermal regulation. "At Technology for Living, we believe equitable access to assistive technology is essential for the well-being and independence of people with disabilities. This pilot is a powerful example of how inclusive innovation can reduce health risks and support safer, more sustainable living environments." said Ean Price, Innovation Strategist, Technology for Living. "This pilot project is a critical step forward for our SCI Climate Futures initiative," said Bill Barrable, CEO of Praxis Spinal Cord Institute. "The project signifies our dedication to advancing innovative, climate-resilient solutions that protect the health and safety of people with spinal cord injuries and others who are vulnerable to extreme heat. At the core of our mission is improving the lives of individuals living with SCI, especially for those most vulnerable to rising temperatures." Next Steps MIMIC Systems will continue working with the pilot household to monitor performance, energy usage, and user experience, while providing ongoing technical support. A second pilot installation site has already been confirmed and is scheduled for deployment in the coming months. This milestone represents a key step toward a climate-resilient future, one that centers on inclusion, accessibility, and sustainability. About Praxis Spinal Cord Institute Praxis Spinal Cord Institute is a Vancouver-based not-for-profit organization that leads global collaboration in spinal cord injury research, innovation, and care. We accelerate the translation of discoveries and best practices into improved treatments for people with spinal cord injuries. Learn more: About Gore Mutual Built on a foundation of financial strength for more than 180 years, Gore Mutual Insurance Company is one of the oldest property and casualty mutual insurers in Canada. With offices in Cambridge, Toronto and Vancouver, Gore Mutual is a Canadian mutual company offering competitive insurance products through trusted broker partners. Every decision and investment made is anchored in the long-term benefits to customers, members and communities. For more information, please visit About Technology for Living Technology for Living (TFL) supports people with severe physical disabilities in living as independently as possible. TFL provides individuals who experience physical barriers with peer support, innovative technologies, respiratory therapy services, and equipment that address unmet needs and promote independence, inclusion, and well-being. Learn more: About MIMIC Systems MIMiC Systems is pioneering solid-state, refrigerant-free heat pump technology to reduce the climate impact of heating and cooling. Unlike traditional systems that depend on compressors and leak high-GWP refrigerants, MIMiC's solution is a quiet, reliable, and emission-free alternative. Our mission is to accelerate the transition to resilient and sustainable heating and cooling systems in buildings and beyond. Learn more:
